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Abstract 
Galectins are a group of animal lectins characterized by their specificity for -galactosides. 
Galectin-2 (Gal-2) is predominantly expressed in the gastrointestinal tract. A proteomic 
analysis identified Gal-2 as a protein that was S-nitrosylated when mouse gastric mucosal 
lysates were reacted with S-nitrosoglutathione, a physiologically relevant S-nitrosylating 
agent. In the present study, recombinant mouse (m)Gal-2 was S-nitrosylated using 
nitrosocysteine (CysNO), which had no effect on the sugar-binding specificity and 
dimerization capacity of the protein. On the other hand, mGal-2 oxidation by H2O2 resulted in 
the loss of sugar-binding ability, while S-nitrosylation prevented H2O2-inducted inactivation, 
presumably by protecting the Cys residue(s) in the protein. These results suggest that S-
nitrosylation by nitric oxides protect Gal-2 from oxidative stress in the gastrointestinal tract. 
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Highlights: 
1. Recombinant mouse galectin-2 (mGal-2) is S-nitrosylated by CysNO treatment. 
2. Both Cys residues (Cys57 and Cys75) of mGal-2 are S-nitrosylated. 
3. mGal-2 sugar-binding and dimerization capacity are unaffected by S-nitrosylation. 
4. H2O2 oxidation induces the loss of mGal-2 lectin activity. 
5. S-nitrosylation of mGal-2 blocks H2O2 oxidation-induced loss of activity. 
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Introduction 
Galectins comprise a group of animal lectins that specifically bind to -galactosides and 
are characterized by an evolutionarily conserved sequence motif in the carbohydrate-binding 
site [1–3]. Galectins are involved in a wide variety of biological processes, including 
development, cell differentiation, tumor metastasis, apoptosis, RNA splicing, and immune 
regulation [4, 5]. 
Interactions between lectins and their carbohydrate ligands play important roles in 
various biological systems. Although the basic sugar structure recognized by mammalian 
galectins such as human galectin-1 (hGal-1) is the N-acetyllactosamine disaccharide unit, the 
sugar-binding specificity of each galectin can be enhanced by branched, repeated, or 
substituted glycans [6,7], suggesting that galectins can interact with a variety of endogenous 
ligands possessing different carbohydrate structures. 
Gal-2 is a member of the galectin family that was first found to be highly expressed in 
gastric cells, predominantly in epithelial cells of the rat stomach [8]. Gastric mucous cells 
also exhibit strong Gal-2 immunoreactivity, with expression observed in the small intestine 
[9] and Gal-2 mRNA detected in human stomach [10]. The amelioration of acute and chronic 
colitis in mice by Gal-2 overexpression [11], and reduced Gal-2 expression in humans 
associated with lymph node metastasis in gastric cancer [12] and in Helicobacter-induced 
gastric cancer progression [13] suggest that Gal-2 has a protective function in the 
gastrointestinal tract. 
Nitric oxide (NO) is an intracellular chemical messenger that is synthesized from L-
arginine by NO synthase (NOS) and participates in signal transduction in variety of 
mammalian cell types, including neurons and vascular endothelial cells [14]. In contrast to 
enzymatic formation by NOS, NO is generated in the stomach by non-enzymatic acid 
reduction of salivary nitrite to exert various physiological functions in the gastrointestinal 
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tract [15–18], including functioning as a barrier in the stomach [19–21]. Furthermore, orally 
administered nitrate ameliorated dextran sulfate sodium-induced acute experimental colitis in 
mice [22]. S-nitrosylation – which involves the coupling of an NO group to the reactive thiol 
of a Cys residue in a polypeptide – is an important post-translational modification detected in 
a variety of proteins [23]; thus, continuous exposure of gastric mucosa to high concentrations 
of NO is predicted to result in the S-nitrosylation of many proteins that could contribute to 
the protection of the stomach lining. 
Gal-2 was identified through a screen of mouse gastric mucosal proteins that are 
uniquely sensitive to S-nitrosylation [24], suggesting Gal-2 exerts a protective effect because 
of S-nitrosylation by NO in the stomach. In this study, recombinant mouse (m)Gal-2 was 
used to test whether the protein is the target of S-nitrosylation and examine the biochemical 
effects thereof. 
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Material and methods 
Construction of wild-type and mutant recombinant mGal-2 expression plasmids – A DNA 
fragment encoding mGal-2 was amplified by PCR using mouse stomach first strand cDNA 
(MD-05, GenoStaff Co., Ltd., Tokyo, Japan) as a template. Forward and reverse primer 
sequences containing NdeI and BamHI sites (underlined), respectively, were 5'-
CATATGTCGGAGAAATTTGAGGTC-3' and 5'-GGATCCGGCTAAGGTCTTCTGAGG-
3', respectively. The PCR product was ligated into the pCR2.1-TOPO vector using the TOPO 
TA cloning kit (Invitrogen, Carlsbad, CA, USA). The pCR2.1-TOPO-mGal-2 plasmid was 
digested with NdeI and BamHI, and the DNA fragment was inserted into the corresponding 
restriction sites of the pET21a vector for protein expression. 
 cDNAs for mGal-2 mutants C57M, C75S, and C57M/C75S were generated by PCR using 
the pCR2.1-TOPO-mGal-2 plasmid and the following primers (substitution sites are 
underlined), as previously described [25]: C57M, 5'-ATGAACACCAGTGAAGGTG-3' and 
5'-GACAATGGTGGATTCATC-3'; C75S, 5'-AGCTTCAGTCCAGGGTCA-3' and 5'-
CATGTGATTTTCTCGTTG-3'; C57M/C75S, 5'-CATTGTCATGAACACCAGTGAAGG-3' 
and 5'-GTGGATTCATCGAAGCGAGG-3'. The PCR products were inserted into the 
pET21a vector for protein expression as described above. 
 
Purification of recombinant mGal-2 – The expression and purification of recombinant wild-
type and mutated forms (C57M, C75S, and C57M/C75S) of mGal-2 were performed as 
previously described [26]. 
 
Measurement of protein concentration – Protein concentration was determined by Bradford’s 
method [27] using bovine serum albumin as standard. 
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Estimation of sulfhydryl groups – The number of free sulhydryl groups on Cys residues of 
recombinant mGal-2 proteins was estimated using Ellman’s reagent (5,5'-dithio-bis-[2-
nitrobenzoic acid]) and by measuring the absorbance at 412 nm [28] using Cys as standard. 
 
S-nitrosylation – The wild-type and mutated forms of mGal-2 protein (1 mg/ml) were 
incubated in ethylenediamine tetraacetic acid-phosphate-buffered saline (EDTA-PBS) (20 
mM NaH2PO4, 150 mM NaCl, 1 mM EDTA, pH 7.2) with or without 1 mM S-
nitrosocysteine (CysNO) for 60 min at room temperature in the dark with constant rotation. 
CysNO was prepared at the time of use by mixing equal amounts of 200 mM Cys in 100 mM 
HCl and 210 mM sodium nitrite in 100 mM HCl. To remove unreacted CysNO, samples 
were ultrafiltered with Amicon Ultra (Millipore, Billerica, MA, USA). 
 
Saville-Griess assay – The number of S-nitrosylated molecules was measured using the 
Saville-Griess assay as previously described [29]. Briefly, S-nitrosylated mGal-2 (wild-type 
or mutated forms) was incubated with 1% sulfanilamide and 0.1% N-
(naphthyl)ethylenediaminde dihydrochloride in the presence 4 mM CuCl2 for 20 min and S-
nitrosylated content was measured photometrically at 540 nm. The amount was calculated 
using defined concentrations of S-nitrosoglutathione as a standard. 
 
Oxidation of mGal-2 by hydrogen peroxide (H2O2) – H2O2 concentration was measured at 
240 nm (240 = 43.6 M
−1
 cm
−1
). S-nitrosylated mGal-2 (0.1 mg/ml, 1 ml) was incubated with 
10 mM H2O2 for 2 h in the dark followed by addition of catalase from bovine liver at a final 
concentration of 100 U/ml (Wako Pure Chemical Industries, Osaka, Japan) to quench excess 
H2O2. 
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Binding of Gal-2 to lactose – S-nitrosylated mGal-2 treated with H2O2 was applied to a 
lactose-immobilized agarose (J-Oil Mills, Inc., Tokyo, Japan) column (bed volume 1 ml). 
After washing with 5 ml EDTA-PBS, the bound mGal-2 was eluted with 2 ml EDTA-PBS 
containing 0.1 M lactose. The eluted fraction was collected (0.5 ml/fraction), and each 
fraction was resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) followed by staining with Bio-Safe Coomassie Brilliant Blue (Bio-Rad, Hercules, CA, 
USA). 
 
Frontal affinity chromatography analysis –Frontal affinity chromatography was carried out 
as previously described [30–32]. Briefly, pyridylaminated (PA)-oligosaccharides were 
dissolved in EDTA-PBS at a concentration of 5 nM and applied to the column (10 × 4.0 mm; 
0.126 ml/ bed volume) through a 2-ml sample loop connected to a Rheodyne 7725i injector. 
The flow rate was controlled by a LC-20AT pump (Shimadzu, Kyoto, Japan) at 0.25 ml/min. 
The sample loop and column were immersed in a 20°C water bath. Elution of PA-
oligosaccharide from the column was monitored with a Shimadzu RF-10AXL fluorescence 
detector at 380 nm (with excitation at 310 nm). The elution volume of the PA-
oligosaccharide of interest was determined as previously described. PA-rhamnose was used 
to determine the elution volume of a PA-oligosaccharide with no affinity for galectins. The 
PA-oligosaccharides used to verify the sugar-binding profile of mGal-2 were PA-001, 002, 
004, 022, 023, 041, 042, 043, 044, 045, 046, 047, and 049, whose structures were described 
in our previous reports [31, 33]. 
 
Hemagglutination assay – Hemagglutination activity was measured as previously reported 
[34]. Briefly, a 25-μl sample of S-nitrosylated mGal-2 was serially diluted 2-fold in a 96-well 
V-shaped microtiter plate, followed by the addition of either 50 μl of EDTA-PBS or 20 mM 
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H2O2 in EDTA-PBS. After incubation at room temperature for 2 h, 25 μl of 4% (v/v) 
glutaraldehyde-fixed rabbit erythrocytes in PBS were added. After standing for 1 h at room 
temperature, the end-point showing the minimum concentration resulting in hemagglutination 
was determined. 
 
Crosslink reaction using BS
3
- After the S-nitrosylation reaction, recombinant mGal-2 (0.01 
mg in 1 ml) was incubated with 0.3 mM bis (sulfosuccinimidyl) suberate (BS
3
) crosslinking 
reagent (Thermo Fisher Scientific Inc., Waltham, MA, USA) for 30 min in EDTA-PBS at 
room temperature. The reaction was terminated by the addition of Tris to a concentration of 
50 mM. Samples were resolved by SDS-PAGE, and the gel was stained with Oriole stain 
(Bio-Rad). 
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Results 
S-nitrosylation of recombinant mGal-2 – Recombinant mGal-2 (wild-type or mutated forms) 
was expressed in Escherichia coli and purified by affinity chromatography. The purified 
protein was S-nitrosylated using CysNO as an NO donor and the stoichiometry of S-
nitrosylation per sulfhydryl group (–SH) was measured with the Saville-Griess assay and 
Ellman’s method. The ratio of mGal-2 S-nitrosylation for wild-type mGal-2 was calculated as 
1.07 moles/mole of –SH. To determine the position(s) of S-nitrosylation, mutant forms of 
mGal-2 (C57M, C75S, and C57M/C75S) were generated as recombinant proteins. The Cys
57
 
residue was changed to Met instead of Ser because the C57S mutant had low expression (data 
not shown) and solubility, as previously reported [35]. For the two mutant forms of mGal-2 
with only one Cys remaining in the polypeptide (C57M and C75S), the S-nitrosylation ratios 
were approximately 0.86 and 0.74 moles/mole of –SH, respectively. Furthermore, no S-
nitrosylation was observed for the C57M/C75S mutant lacking Cys residues. 
 
Sugar-binding capacity of mGal-2 is unaffected by S-nitrosylation – To determine the effect 
of S-nitrosylation on mGal-2 function, the sugar-binding capacity of mGal-2 was assessed. 
Following S-nitrosylation, the protein was exposed to a lactose-immobilized agarose column. 
In the absence of S-nitrosylation, recombinant mGal-2 was adsorbed to the column and eluted 
with 0.1 M lactose (Fig. 1a). Similarly, S-nitrosylated mGal-2 was adsorbed to the column 
and eluted with 0.1 M lactose (Fig. 1b), suggesting that S-nitrosylation did not alter the -
galactoside-binding capacity of mGal-2. To examine the effects of S-nitrosylation on sugar-
binding by mGal-2 in more detail, recombinant mGal-2 protein with or without S-
nitrosylation was immobilized to agarose resin and analyzed by frontal affinity 
chromatography. There were no significant changes in the binding affinity of mGal-2 to the 
PA-oligosaccharides examined (Fig. 1c). Furthermore, when recombinant and S-nitrosylated 
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mGal-2 were labeled with Cy3 and their sugar-binding profiles were analyzed by 
glycoconjugate microarray [36], there were no significant differences detected (data not 
shown). 
 
Dimerization of mGal-2 is unaffected by S-nitrosylation – mGal-2 dimerization was analyzed 
by incubating the protein with the crosslinker BS
3
, followed by SDS-PAGE and Oriole 
staining (Fig. 2). A similar dimer-monomer ratio was observed for mGal-2 with and without 
S-nitrosylation. 
 
H2O2-induced mGal-2 inactivation is abrogated by S-nitrosylation – Unlike untreated mGal-2 
(Fig. 1a), recombinant mGal-2 was inactivated by treatment with 10 mM H2O2 for 2 h, as 
evidenced by the absence of interaction between H2O2-treated mGal-2 and immobilized 
lactose in the agarose column (Fig. 3a). In contrast, S-nitrosylated mGal-2 was able to bind to 
the lactose-immobilized agarose column even after H2O2 treatment and was eluted with 
lactose (Fig. 3b), suggesting that the oxidative inactivation of mGal-2 was prevented by S-
nitrosylation. Similarly, S-nitrosylation preserved the hemagglutination activity of mGal-2. 
As shown in Figure 4, the hemagglutination activity was lost upon exposure to H2O2 prior to 
the addition of a rabbit erythrocyte suspension (line C), even when the mGal-2 concentration 
was 2
5
-fold higher than the minimum concentration that induced hemagglutination in the 
absence of H2O2 (line A). S-nitrosylated mGal-2 retained hemagglutination activity (line B) 
even after H2O2 treatment (line D). These results indicate that S-nitrosylation protects mGal-2 
against oxidative inactivation by H2O2. 
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Discussion 
In this study, the ratio of recombinant wild-type mGal-2 S-nitrosylated by CysNO was 
calculated as 1.07 moles of S-nitrosylation/mole of –SH, suggesting that the two Cys residues 
(Cys
57
 and Cys
75
) were both fully S-nitrosylated, which was supported by the fact that no S-
nitrosylation was observed for the C57M/C75S mutant lacking Cys. When equivalent 
amounts of wild-type or mutated protein were used for S-nitrosylation, the ratio was 
1:0.48:0.42:0 for wild-type:C57M:C75S:C57M/C75S. Furthermore, the ratio of S-
nitrosylation was approximately 0.86 and 0.74 moles/mole of –SH for the C57M and C75S 
mGal-2 mutants, respectively. These results suggest that the single remaining Cys in the two 
mutants (Cys
75
 in C57M mutant and Cys
57
 in C75S) were both S-nitrosylated by CysNO. 
Since the generated mutants were adsorbed to -galactoside-containing columns and eluted 
with lactose, and no differences in sugar-binding profiles were detected by frontal affinity 
chromatography—implying that sugar-binding profiles were similar between mutant and 
wild-type mGal-2—it was concluded that the mutants have the same biochemical properties 
as wild-type mGal-2. 
Cys
57
 and Cys
75
 are highly conserved in Gal-2 across mammals. According to the X-ray 
crystal structure of human Gal-2 in complex with lactose [37], Cys
57
 is located in the middle 
of the carbohydrate-binding cassette with its side chain sulfhydryl group (a potential site for 
S-nitrosylation) protruding to the side opposite the -sheet that binds lactose. 
We speculated that S-nitrosylation could alter the sugar-binding capacity of mGal-2, 
especially at Cys
57
; S-nitrosylated mGal-2 was therefore assessed for its capacity to bind to 
lactose-immobilized agarose columns and was also analyzed by frontal affinity 
chromatography and glycoconjugate microarray. There were no differences in the sugar-
binding profile or hemagglutination activity between mGal-2 with and without S-
nitrosylation, even though Cys
57
 appeared to be S-nitrosylated. These combined with the 
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results from the BS
3
 crosslinking experiment indicate that S-nitrosylation does not affect 
mGal-2 dimerization; this is likely because—based on the crystal structure of human Gal-2—
the two Cys residues are distant from the surface that engages in dimer formation. 
However, an interesting difference between mGal-2 with and without and S-
nitrosylation was observed when the microtiter V-plate was left on the bench after the 
measurement of hemagglutination activity: erythrocytes remained hemagglutinated by S-
nitrosylated mGal-2 but not by mGal-2 after a few days at room temperature. Since it was 
assumed that the loss of hemagglutination activity was due to mGal-2 oxidation, mGal-2 was 
oxidized by treatment with H2O2, one type of reactive oxygen species (ROS) produced in the 
stomach upon inflammation caused by Helicobacter pylori or other types of infection [38]. 
H2O2 treatment resulted in the loss of mGal-2 activity, an effect that was abrogated by S-
nitrosylation. Although a small amount of mGal-2 was still adsorbed to the lactose-
immobilized agarose column and was eluted with 0.1 M lactose, this appeared to be the result 
of insufficient oxidation by H2O2.  
It is possible that S-nitrosylation of the two Cys residues inhibited the oxidation of these 
residues. Some proteins such as protein-tyrosine phosphatase 1B are protected against 
oxidation-induced inactivation by S-nitrosylation of Cys residues [39]. Since Gal-2 exists 
predominantly in the gastrointestinal tract where it has a protective role, NO produced in the 
stomach may induce S-nitrosylation of Gal-2, thereby protecting the protein from oxidation 
by ROS so that it retains its activity. 
On the other hand, a very small amount of S-nitrosylated mGal-2 lost lectin activity by 
oxidation and were therefore not retained by the lactose-immobilized agarose column, 
possibly because H2O2 treatment may have resulted in oxidation of residues other than the 
two Cys residues. 
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Gal-1 has six Cys residues whose oxidative states dictate Gal-1 function [40–44]. On the 
other hand, the monomer-dimer equilibrium of Gal-1 regulates its sensitivity to oxidative 
inactivation [45]. Furthermore, human Gal-1 may also be a substrate for S-nitrosylation [46]. 
Taken together, these results suggest that S-nitrosylation is an important modification for 
regulating galectin activity in animals. 
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Figure legends 
Figure 1. Effect of S-nitrosylation on sugar-binding profiles of recombinant mGal-2. (a, 
b) Adsorbance to a lactose-immobilized agarose column. Purified recombinant mGal-2 was 
added to the column following the S-nitrosylation reaction. The column was washed with 
EDTA-PBS and adsorbed proteins were eluted with EDTA-PBS containing 0.1 M lactose. 
The protein concentration of each fraction was measured and analyzed by SDS-PAGE 
followed by gel staining with Coomassie Brilliant Blue. Since only recombinant mGal-2 
protein was applied to the column, the bands at 15 kDa corresponded to recombinant mGal-2; 
bands for each fraction are shown at corresponding areas in each gel. Profiles of recombinant 
non-nitrosylated mGal-2 (a) and nitrosylated mGal-2 (b) eluted from lactose-immobilized 
agarose.  
(c) Frontal affinity chromatography analysis of recombinant mGal-2 with or without S-
nitrosylation. After the S-nitrosylation reaction, recombinant mGal-2 protein was 
immobilized on N-hydroxysuccinimide-activated agarose. Ka values of immobilized mGal-2 
after and without S-nitrosylation are shown as gray and black bars, respectively. 
 
Figure 2. Detection of mGal-2 dimer formation using the BS
3
 crosslinker. BS
3
 was added 
to recombinant mGal-2 solution with (CysNO+) or without (CysNO−) S-nitrosylation. The 
reaction mixture was analyzed by SDS-PAGE and the gel was stained with Oriole. 
 
Figure 3. Loss of sugar-binding capacity of recombinant mGal-2 after H2O2 treatment 
and protective effect of S-nitrosylation against oxidation-induced protein inactivation. 
Purified recombinant mGal-2 was treated with 10 mM H2O2 for 2 h in the dark, and was 
added to a lactose-immobilized agarose column, washed with EDTA-PBS, and eluted with 
lactose. Elution profiles of mGal-2 were verified by measuring the protein concentration of 
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each fraction (0.5 ml each), which was analyzed by SDS-PAGE. Bands at around 15 kDa, the 
molecular weight of the mGal-2 monomer, were detected by Coomassie Brilliant Blue 
staining. (a, b) Profiles of recombinant non-nitrosylated mGal-2 (a) and mGal-2 nitrosylated 
before H2O2 treatment (b) eluted from lactose-immobilized agarose. 
 
Figure 4. Loss of hemagglutination activity of recombinant mGal-2 after H2O2 
treatment and protective effect of S-nitrosylation against oxidation-induced protein 
inactivation. Purified recombinant mGal-2 (250 g/ml in EDTA-PBS) was diluted 2-fold in 
a 96-well microtiter plate and treated with H2O2 for 2 h in the dark. A suspension of 
glutaraldehyde-fixed rabbit erythrocytes in EDTA-PBS was added and hemagglutination 
activity was determined after 1-h incubation. 
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